Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings. Read more

Our latest news for ‘New publication’

We are proud to be leading the way in providing more patient-centric solutions for people with liver disease that helps them and their physician make informed decisions about their care.

Read our latest news to find out more about how we are helping to improve the understanding of liver disease.

New publication: Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis Posted: June 16, 2021

NAFLD NASH Liver Disease New publication

LiverMultiScan^® shown to be the best non-invasive predictor of disease activity in autoimmune hepatitis, demonstrating its potential to influence clinical treatment Posted: March 3, 2021

New publication AIH Autoimmune hepatitis LiverMultiScan

New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis Posted: February 24, 2021

NASH NAFLD LiverMultiScan Liver Disease New publication

LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials. Posted: February 4, 2021

NAFLD NASH LiverMultiScan New publication ClinicalTrials

Perspectum’s RADIcAL1 trial - addressing the health economic burden of invasive diagnostics for NAFLD and NASH Posted: December 9, 2020

RADIcAL NAFLD NASH LiverMultiScan Liver Disease New publication

Hepatica - new tool informs surgeons about previously undiagnosed background liver disease, helping to improve surgical decision-making in liver cancer care Posted: December 2, 2020

Hepatica liver cancer Liver Disease New publication

New monitoring tool could be a positive change on the horizon for children with autoimmune hepatitis Posted: October 6, 2020

AIH LiverMultiScan New publication

Perspectum and UK Biobank help to uncover genetic marker associated with fatty liver disease Posted: September 24, 2020

LiverMultiScan Genetics Population Imaging New publication

New non-invasive MRI biomarker for liver disease could cut costs for drug trials Posted: September 22, 2020

LiverMultiScan Liver Disease NAFLD NASH New publication